CompanyGraph
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
301096 · SZSE · China
hzbio-s.comFinancials as of FY2025
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- FinancialsAltman Z-Score 3.1: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.33BCNY791.18M · vs all stocks (USD)
Revenue (TTM)
709.72MCNY105.41M · vs all stocks (USD)
Profit Margin
-7.24%Beta
0.4680xvs all stocks
52-Week Change
-10.54%vs all stocks
Market Capitalization
5.33BCNY791.18M · vs all stocks (USD)
Enterprise Value
6.06BCNY899.67M · vs all stocks (USD)
Forward P/E
64.82xPrice to Sales (TTM)
7.81xPrice to Book (MRQ)
2.20xEnterprise to Revenue
8.54xEnterprise to EBITDA
52.86xGross Margin
50.50%Profit Margin
-7.24%Operating Margin
7.45%Return on Assets (TTM)
-0.75%Return on Equity (TTM)
-2.03%Revenue (TTM)
709.72MCNY105.41M · vs all stocks (USD)
Revenue per Share (TTM)
6.53CNYUpdated Aug 20, 2026Quarterly Revenue Growth
24.60%Gross Profit (TTM)
288.74MCNY42.88M · vs all stocks (USD)
EBITDA (TTM)
120.99MCNY17.97M · vs all stocks (USD)
Net Income (TTM)
-51.39MCNY-7.63M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
99.46%Operating Cash Flow (TTM)
-91.47MCNY-13.58M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-179.97MCNY-26.73M · vs all stocks (USD)
Revenue
677.99MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
410.16MCNYFY2025 · Dec 31, 2025Gross Profit
267.83MCNYFY2025 · Dec 31, 2025Operating Income
-25.74MCNY-3.82M · vs all stocks (USD)
Pre-tax Income
-91.14MCNYFY2025 · Dec 31, 2025Income Tax Expense
-743.43KCNYFY2025 · Dec 31, 2025Net Income
-90.40MCNYFY2025 · Dec 31, 2025EBIT
-70.12MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
120.99MCNYFY2025 · Dec 31, 2025Research & Development
189.87MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
26.83MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.16MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.96MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
21.02MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.8300CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.8300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
108.91MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
108.91MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-90.40MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-287.25MCNYFY2025 · Dec 31, 2025Free Cash Flow
-384.74MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
280.48MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-90.40MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.76MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-211.65MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.96MCNYFY2025 · Dec 31, 2025Capital Expenditures
-97.49MCNYFY2025 · Dec 31, 2025Purchase of Investments
-34.87MCNYFY2025 · Dec 31, 2025Sale of Investments
4.34MCNYFY2025 · Dec 31, 2025Other Investing Activity
7.22MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-120.81MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.06BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-899.88MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-20.52MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.04MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
139.84MCNYFY2025 · Dec 31, 2025Shares Outstanding
109.23MSharesUpdated Aug 20, 2026Float Shares
59.13MSharesUpdated Aug 20, 2026% Held by Insiders
40.85%vs all stocks
% Held by Institutions
7.84%vs all stocks
Total Cash (MRQ)
456.51MCNY67.80M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.21CNYUpdated Aug 20, 2026Total Debt (MRQ)
1.01BCNY150.03M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4038xCurrent Ratio (MRQ)
1.87xBook Value per Share (MRQ)
23.07CNYUpdated Aug 20, 2026Total Assets
3.69BCNY547.48M · vs all stocks (USD)
Total Current Assets
1.55BCNYFY2025 · Dec 31, 2025Total Liabilities
1.20BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.13BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
277.40MCNYFY2025 · Dec 31, 2025Total Current Liabilities
919.91MCNYFY2025 · Dec 31, 2025Cash
280.95MCNYFY2025 · Dec 31, 2025Cash Equivalents
11.65MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
292.60MCNYFY2025 · Dec 31, 2025Other Short-term Investments
80.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
467.21MCNYFY2025 · Dec 31, 2025Inventory
176.44MCNYFY2025 · Dec 31, 2025Accounts Payable
130.14MCNYFY2025 · Dec 31, 2025Short-term Debt
680.98MCNYFY2025 · Dec 31, 2025Long-term Debt
191.84MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
61.84MCNYFY2025 · Dec 31, 2025Common Stock (Book)
109.23MCNYFY2025 · Dec 31, 2025Retained Earnings
268.48MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.49BCNY369.66M · vs all stocks (USD)
Treasury Stock
50.00MCNYFY2025 · Dec 31, 202552-Week Low
35.20CNYUpdated Aug 20, 202652-Week High
77.17CNYUpdated Aug 20, 202652-Week Change
-10.54%vs all stocks
Beta
0.4680xvs all stocks
50-Day MA
48.91CNYUpdated Aug 20, 2026200-Day MA
53.21CNYUpdated Aug 20, 2026Avg 10-Day Volume
3.59MSharesUpdated Aug 20, 2026Avg 30-Day Volume
4.26MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.4700CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.51Profit Margin: -0.07
Financial Health
Altman Z-Score 3.1: safe zoneNotable
Altman Z-Score: 3.10
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Companies that share the same coordination system — how they create, deliver, or capture value.
CytomX Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Lummy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow